DoD Multiple Sclerosis Early Investigator Research Award

The Multiple Sclerosis Research Program Early Investigator Research Award is a federal funding opportunity administered through the Defense Health Agency Contracting Activity and managed by the Congressionally Directed Medical Research Programs under the Defense Health Agency Research and Development office. The opportunity is designed to support early-career postdoctoral investigators pursuing research related to multiple sclerosis under the mentorship of experienced MS researchers. The program aligns with the broader mission of the Multiple Sclerosis Research Program, which seeks to prevent, cure, reverse, or slow the progression of multiple sclerosis and reduce its impact on Service Members, Veterans, military families, and the broader public. The funding announcement emphasizes high-impact, innovative, and scientifically rigorous research relevant to the prevention, pathogenesis, assessment, treatment, and eventual cure of MS. The award mechanism specifically targets postdoctoral fellows who have four years or less of postdoctoral research experience at the time of application submission. Faculty members and non-postdoctoral personnel are not eligible. Applicants must possess a doctoral degree or equivalent and commit at least 50 percent effort toward the proposed research project. The opportunity is open to domestic and foreign organizations, including nonprofit organizations, for-profit organizations, public and private entities, and intramural and extramural Department of War organizations. Applications must include at least one qualified mentor with demonstrated experience in MS research and mentoring. The program strongly emphasizes development of the applicant into an independent MS researcher through a structured Researcher Development Plan and sustained mentorship activities. All projects must address at least one of four designated focus areas. These include central nervous system repair and regenerative approaches in MS; correlates of disease activity and progression using existing patient data and specimens; biology and measurement of MS symptoms; and mechanisms contributing to MS etiology, onset, and progression. The announcement provides extensive examples of acceptable and prohibited research topics within each focus area. Clinical trials are not permitted under this funding opportunity. Projects involving animal studies must include an Animal Research Plan and justify the relevance of the selected model to human MS biology. Projects utilizing pre-existing patient cohorts for disease correlates research must provide formal confirmation of access to specimens and data available at the time of application submission. Funding support is limited to a maximum total cost of $300,000 for a performance period of up to two years. Approximately $1.2 million is expected to be allocated to fund about four awards. Indirect costs are allowed in accordance with negotiated institutional rates, and all direct and indirect subaward costs must be included within the primary award budget. Allowable expenses include travel supporting multi-institutional collaboration and attendance at one scientific or technical meeting per year to disseminate project findings. The announcement specifically prohibits requests for additional scientific meeting travel beyond these limits. Cost sharing or matching contributions are not required. Awards are expected to be funded using fiscal year 2026 appropriations and issued no later than September 30, 2027. The application process involves both a pre-application and full application phase. Applicants must first submit a Letter of Intent through the Electronic Biomedical Research Application Portal. The pre-application also requires identification of three individuals who will provide confidential recommendation letters, including one from the primary mentor. Following pre-application submission, applicants may submit a full application through Grants.gov for extramural organizations or eBRAP for eligible intramural organizations. Full applications require extensive documentation, including a Project Narrative, Technical Abstract, Lay Abstract, Statement of Work, Impact Statement, Researcher Development Plan, Eligibility Statement, supporting documentation, biosketches, budget materials, and additional compliance documentation. Depending on project design, applicants may also need an Animal Research Plan or documentation confirming access to existing specimens and datasets. Applications undergo a two-tier review process consisting of peer review followed by programmatic review. Peer reviewers evaluate the scientific merit of the proposal, the qualifications and potential of the principal investigator, the mentor team's capabilities, the rigor and feasibility of the research plan, the quality of the Researcher Development Plan, and the projected impact on MS research and patient care. Additional considerations include reproducibility, statistical rigor, data sharing plans, and research environment. Programmatic review then assesses relevance to program priorities, portfolio balance, innovation, and overall impact. Applications may be rejected or withdrawn for administrative reasons such as missing required attachments, proposing clinical trials, exceeding page limits, or failing to align with the designated focus areas. The timeline for the funding opportunity includes a pre-application deadline of July 30, 2026, a full application deadline of August 13, 2026, and a confidential recommendation letter deadline of August 20, 2026. Peer review is scheduled for December 2026 and programmatic review for February 2027. Award notifications are typically posted within six weeks after programmatic review. Applicants are advised to begin registration with SAM.gov, Grants.gov, and eBRAP early because account activation can take several weeks. Technical support is available through the eBRAP Help Desk and the Grants.gov Support Center for assistance with submission requirements and portal issues.

Ensure the proposal clearly aligns with at least one FY26 MSRP EIRA focus area; demonstrate strong mentor commitment and MS research expertise; provide rigorous experimental design and statistical methodology; include a strong individualized Researcher Development Plan; clearly explain short term and long term impact on MS research and patient care; emphasize reproducibility and feasibility of the project